Comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190 vs 3 M Syndrome C1848862
Clinical comparison between 3 Phosphoglycerate Dehydrogenase Deficiency and 3 M Syndrome for differential diagnosis and treatment planning.
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
A rare metabolic disorder impairing the body's ability to produce serine, an essential amino acid. It primarily affects the nervous system, causing developmental delay, seizures, and movement difficulties. Management includes serine supplementation and anticonvulsants as needed.
3 M Syndrome C1848862
A rare genetic syndrome causing severe short stature and distinctive facial features. Affects bone development. Treatment involves growth monitoring and orthopedic care.
6 comparison axes
Onset
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
0-5
3 M Syndrome C1848862
0-null
Onset patterns differ
Severity
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
severe
3 M Syndrome C1848862
moderate
Different severity levels
Chronic
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
Chronic
3 M Syndrome C1848862
Chronic
Differing course
Communicable
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
No
3 M Syndrome C1848862
No
Different transmission
Body System
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3 M Syndrome C1848862
musculoskeletal
Same/different system
Category
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3 M Syndrome C1848862
genetic
Different category
Bottom line
3-phosphoglycerate-dehydrogenase-deficiency-C0580190 and 3-m-syndrome-C1848862 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3 M Syndrome C1848862 | Discriminating power |
|---|---|---|---|
| Neurologic features | Developmental delay, seizures, and movement difficulty are described. | Neurologic disease is not established; growth and facial features predominate. | High |
| Growth and skeleton | Not described as a primary skeletal-growth disorder. | Severe short stature and impaired bone development are central. | High |
| Onset and severity | Early-childhood onset is listed, with a severe chronic course. | Onset timing is unspecified; severity is listed as moderate and chronic. | Moderate |
When to favor each condition
Choose 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 when
Young child with seizures and developmental delay
This matches the described nervous-system effects of impaired serine production.
Moderate
Suspected inborn error of metabolism
The source classifies the condition as metabolic rather than primarily skeletal.
High
Need for metabolic and seizure-focused care
Described management includes serine supplementation and anticonvulsants when needed.
Moderate
Choose 3 M Syndrome C1848862 when
Severe short stature with distinctive facial features
These are the core features supplied for 3-M syndrome.
High
Suspected genetic skeletal condition
The source places it in musculoskeletal and genetic categories.
Moderate
Growth or orthopedic concerns without described seizures
Described care centers on growth monitoring and orthopedic management.
Moderate
How key tests differ
| Test | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3 M Syndrome C1848862 | Interpretation |
|---|---|---|---|
| Serine-related biochemical testing | May support a serine-synthesis disorder; no cutoff is supplied. | Not described as the defining test. | An abnormal result is not a diagnosis and needs specialist review. |
| Targeted genetic testing | May be used when a PHGDH-related disorder is suspected. | May assess genes associated with 3-M syndrome when suspected. | Gene choice should follow phenotype; results require clinical interpretation. |
| Growth and skeletal evaluation | Not the primary discriminator in the source. | May document short stature and bone-development abnormalities. | Measurements or imaging support assessment but do not alone confirm diagnosis. |
Prognosis comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
- Outcome
- Described as severe and chronic, with neurologic involvement; survival is not quantified.
- Factors
- Developmental course, seizures, and response to specialist care may be relevant.
3 M Syndrome C1848862
- Outcome
- Described as moderate and chronic, centered on severe short stature; mortality is not established.
- Factors
- Growth pattern, skeletal complications, and access to orthopedic and genetic care.
Time frame: Both are chronic and often considered in childhood; long-term outcomes are not quantified.
Confirmed diagnosis, complication pattern, and individualized specialist care influence outlook.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic complications | Seizures, developmental delay, and movement difficulty are described. Not established by the supplied description. Neurologic risk should be assessed individually. |
| Skeletal and growth complications | Not described as the main complication. Severe short stature and bone-development problems may require orthopedic care. Functional impact is variable and not quantified here. |
| Long-term care burden | May involve ongoing metabolic treatment and seizure management. May involve growth surveillance and orthopedic care. Treatment doses and outcomes are not established by this source. |
Patient education highlights
- HighSimilar names, different conditions
One is a metabolic serine disorder; the other is a genetic growth and skeletal syndrome.
- HighSpecialist diagnosis
Physical features or test abnormalities are not definitive alone and need clinician interpretation.
- MediumIndividualized care
Reported approaches differ: serine and seizure care versus growth monitoring and orthopedic care.